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Abstract:Glycosylation is a very frequent and functionally important post-translational protein 
modification that undergoes profound changes in cancer. Growth and death factor receptors and 
plasma membrane glycoproteins, which upon activation by extracellular ligands trigger a signal 
transduction cascade, are targets of several molecular anti-cancer drugs. In this review, we provide 
a thorough picture of the mechanisms bywhich glycosylation affects the activity of growth and 
death factor receptors in normal and pathological conditions. Glycosylation affects receptor activity 
through three non-mutually exclusive basic mechanisms: (1) by directly regulating intracellular 
transport, ligand binding, oligomerization and signaling of receptors; (2) through the binding of 
receptor carbohydrate structures to galectins, forming a lattice thatregulates receptor turnover on 
the plasma membrane; and (3) by receptor interaction with gangliosides inside membrane 
microdomains. Some carbohydrate chains, for example core fucose and β1,6-branching, exert a 
stimulatory effect on all receptors, while other structures exert opposite effects on different receptors 
or in different cellular contexts. In light of the crucial role played by glycosylation in the regulation 
of receptor activity, the development of next-generation drugs targeting glyco-epitopes of growth 
factor receptors should be considered a therapeutically interesting goal. 




Cells receive the order to proliferate, survive, or die usually from the outside, in the form of 
small proteins that bind to specific receptors on their surface. Binding of these ligands, which include 
growth factors, cytokines, hormones, and death-inducing molecules, to their receptors triggers 
intracellular signaling cascades, which ultimately lead to gene transcription. Most of these receptors 
are classical tyrosine kinase receptors (RTKs). They are homo- or heterodimers in which the ligand 
binding triggers receptor dimerization and the autophosphorylation of tyrosine residues in the 
cytoplasmic portion, generating a transduction signal. The activity of a specific receptor, its turnover, 
and its ability to interact with adaptor molecules are finely regulated by post-translational 
mechanisms, including glycosylation [1–3]. In this review, after a brief outline of glycosylation, we 
will address the different mechanisms bywhich glycosylation modulates receptor activity. Notch 
receptors, which exhibit a very peculiar kind of glycosylation, have been the topic of recent reviews 
[4–6] and are not discussed here. 
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2. Outline of N- and O-Glycosylation 
Glycoconjugates, which include glycoproteins, proteoglycans, and glycolipids, are biological 
molecules comprised of a sugar portion linked to proteins or lipids. The two major types of protein- 
linked sugar chains in glycoproteins are referred to as N-linked and O-linked. In the first, the sugar 
moiety is linked through a bond between the reducing N-acetylglucosamine (GlcNAc) residue and 
the nitrogen of asparagine; in the second, through a link between the reducing N-acetylgalactosamine 
(GalNAc) residue and the hydroxyl groups of serine or threonine. Other types of sugar–protein 
structures, such as O-GlcNAc, O-mannose, or O-fucose, play specific roles but their discussion is 
beyond the scope of this review. The biosynthesis of the sugar portion of glycoconjugates is mediated 
by glycosyltransferases. These enzymes transfer monosaccharides from a donor substrate (usually a 
sugar-nucleotide, such as UDP-GlcNAc or CMP-sialic acid) to an acceptor, which can be a nascent 
sugar chain. The biosynthesis of N- and O-linked chains follows completely different pathways. N-
linked chains are synthesized as a pre-assembled dolichol-linked glycan comprised of twoGlcNAc, 
nine mannose (Man), and three glucose (Glc) residues in the rough endoplasmic reticulum, which 
arethen transferred en bloc to an asparagine residue of the nascent protein [7]. A necessary but not 
sufficient consensus motif for N-glycosylation is Asn-X-Ser/Thr, where X is any aminoacid except 
proline. Successively, the threeGlc and a total of six Man residues are trimmed during transit along 
the exocytic pathway and replaced with GlcNAc, galactose (Gal), sialic acid (Sia), and fucose (Fuc) 
residues, arranged in a variety of structures expressed on several branches (antennae), whose number 
usually ranges from two to four. On the contrary, the biosynthesis of O-linked chains proceeds from 
the stepwise addition of single monosaccharides along the exocytic pathway. The addition of the first 
GalNAc residue to the peptide can be mediated by 20 different peptide:GalNac transferases with 
subtle substrate differences [8] (see Table 1 for a list of glycosyltransferases mentioned in this review 
and their cognate carbohydrate structures). Given their ubiquitous presence and abundance in all 
cellular compartments, extracellular spaces, and body fluids, glycans exert their biological effects by 
modulating functions of proteins and lipids to which they are attached, acting as a “fine tuning” of 
their biological activities [9]. In cancer, glycosylation undergoes profound changes (reviewed in 
[10,11]) thataffect a variety of membrane proteins, including growth factor receptors. Altered 
glycosylation of growth factor receptors is partly responsible for their deranged activity and the 
cancer cell phenotype. 
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Table 1. Glycan structures involved in the regulation of receptor activity. 
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GD1α Glycolipid α2,6 sialyltransferase 5 ST6GALNAC5 ST6GALNAC5 MET [93]  
Monosaccharides are represented according to the following code: . The depicted N-linked chain, 






GlcNAc GalNAcMan Gal Sia FucGlc
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3. General Mechanisms by Which Glycosylation Affects Receptor Activity 
The mechanisms by which glycosylation of membrane receptors affects their activity, 
modulating the flow of information from the plasma membrane to the nucleus (outside-in) and 
eventually transcription activity [10,94], can be classified in the following three broad conceptual 
groups. It should be emphasized that the three mechanisms outlined below are not mutually 
exclusive. 
3.1. Direct Effect of Glycosylation 
Whole sugar chains, such as N-glycans or specific carbohydrate structures, affect intracellular 
transport, ligand binding, oligomerization and signaling of the receptors [15,95]. Using N-
glycosylation inhibitors, such as tunicamycin, or N-glycosylation sites mutagenesis it has been 
possible to assess the role played by N-glycans as a whole. For instance, it has long been known that 
the use of the inhibitor tunicamycin to prevent N-glycosylation can negatively affect the initial folding 
of ER-synthesized proteins. On the other hand, the role played by specific sugar epitopes, for example 
core fucose or the Lewis antigens (Table 1), is indicated by studies in which specific 
glycosyltransferases have been genetically manipulated in cell lines [96] or mice [28]. 
3.2. Galectin Binding 
Galectins, extracellular multivalent lectins [97], bind to the carbohydrate structures of the 
receptors forming a lattice (Figure 1), which regulates their turnover on the plasma membrane [98], 
usually potentiating the signaling downstream [99]. The ability of receptors to bind galectins is 
critically dependent on the degree of branching of their N-linked chains (Figure 1), in particular on 
the presence of the β1,6-branch synthesized by GlcNAc transferase-V (GnT-V) encoded by the 
MGAT5 gene (Table 1). A complex mechanism links β1,6-branching, Golgi concentration of UDP-
GlcNAc (the donor substrate of GlcNAc transferases) and the turnover of receptors on the membrane 
[100]. In fact, high glucose concentration results in increased Golgi levels of UDP-GlcNAc and 
MGAT5 activity, which, in turn, stimulate β1,6-branching, leading to the biosynthesis of binding sites 
for galectin-3. Interaction of receptors with galectin-3 and their consequent entrapment in a lattice 
regulates their permanence on the cell membrane [101]. It has been shown that growth-promoting 
receptors (e.g., the receptors of epidermal growth factor, EGFR; of insulin like growth factor, IGFR; 
of fibroblast growth factor, FGFR) exhibit a higher number of N-linked chains than inhibitory 
receptors (e.g., transforming growth factor-β receptor, TGFBR and cytotoxic T-lymphocyte antigen 4, 
CTLA-4) [100,102]. The increase of intracellular glucose concentration generates a hyperbolic 
activation profile for receptors with a high number of N-glycans but a sigmoid profile for those with 
a lower number. This makes inhibitory receptors much more sensitive to increasing glucose 
concentration than growth-promoting receptors, resulting in their switch-like responses (Figure1) 
[100,102]. 
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Figure1. Schematic representation of a plasma membrane area with two different generic growth 
factor receptors. In light blue is represented a receptor with a high number of N-linked chains bearing 
the β1,6-branched polylactosaminic chains, which are ideal ligands for galectins (in red). The binding 
of galectins to polylactosaminic chains results in a lattice, which stabilizes receptors on the cell 
membrane. In pink is represented a receptor with a small number of N-linked chains with a few β1,6-
branching and no polylactosaminic chains. This type of glycosylation makes galectins unable to form 
a lattice and stabilize receptors. Sugar codes are as in the legend of Table 1. 
3.3. Interaction with Gangliosides 
Gangliosides are sialic acid containing glycolipids (Table 1) that can modulate receptor activity 
because they colocalize with growth factor receptors and a variety of other molecules in specialized 
areas of the plasma membrane known as microdomains (Figure 2) [103,104]. Lipid rafts and 
tetraspanin-enriched microdomains are distinct structures. In both of them,signals coming from 
growth factor receptors are integrated with those coming from gangliosides and other microdomain 
components and conveyed to the nucleus by signal transduction pathways [105]. Glycosylation can 
regulate this system at the level of membrane receptors, gangliosides, or other microdomain 
components, such as cell adhesion molecules. Glycosylation of these components results from the 
activity of glycosyltransferases and glycosidases. A remarkably important glycosidase family is the 
NEU family of sialidases that embraces four enzymes (NEU1-4), which cleave sialic acids from 
glycoconjugates in different cellular localizations [106,107]. 
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Figure 2. Schematic representation of membrane microdomains. The complex interactions among 
RTKs, integrins and tetraspanins with signal transduction molecules leading to gene transcription, 
are depicted in a simplified representation. The left part of the Figure represents a tetraspanin 
microdomain, while the right part represents a caveola with caveolin-1. Sugar codes are as in the 
legend of Table 1. 
4. How Glycosylation Modulates the Activity of Specific Receptors 
4.1. Receptors of the ERBB Family 
The ERBB family of RTK consists of four members (ERBB1-4), of which ERBB1 is also known as 
the EGF receptor (EGFR), while ERBB2 as HER2. Receptor homo- or hetero- dimerization induced by 
ligand binding triggers intracellular signaling, mainly through mitogen-activated protein kinase 
(MAPK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and 
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathways [108]. EGFR is also present in 
the nucleus of carcinoma cells, where it transcriptionally regulates several genes, including CCND1 
encoding cyclin D1 [109]. Overexpression, increased activity or mutations of EGFR are described in 
various human epithelial tumors, indicating its causative role in the etiology of human epithelial 
cancers. Thus, targeting of EGFR has been actively pursued over the last three decades as a treatment 
strategy. From these efforts, two fundamental approaches have proven to be useful. One approach 
involves the use of small molecule tyrosine kinase inhibitors such as Erlotinib (Tarceva) and Gefitinib 
(Iressa), both EGFR-specific tyrosine kinase inhibitors, while a second approach uses monoclonal 
antibodies (mAbs) such as Cetuximab (Erbitux), which prevent both ligand binding and dimerization 
with other HER family members. On the other hand, HER2 is the target of the monoclonal antibody 
Trastuzumab (Herceptin). These molecular drugs are in clinical use for the treatment of several 
cancers. 
4.1.1. Direct Effect of Glycosylation on ERBB Activity 
EGFR has 11 typical (N-X-S/T) and 4 atypical (N-X-C) N-glycosylation consensus sequences and 
N-glycans account for about 40 kDa of its total molecular mass [2]. The number of potential N-
glycosylation sites of the other ERBB members ranges from 8 of ERBB2 to 11 of ERBB4 [2]. As shown 
by site directed mutagenesis, some of the several N-glycans exposed on the extracellular region of 
ERBB receptors can directly modulate their biological activity, probably by preventing ligand-
independent dimerization [12–14,110] and modulating intracellular transport [21]. 
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Core fucose is required for the ligand binding ability [24] and intracellular signaling of EGFR 
[23]. In fact, it has been reported that, in the absence of core fucosylation, the biological function of 
the receptor may decrease and the process of hepatic carcinogenesis is inhibited [25]. Bisecting 
GlcNAc inhibits EGFR and integrin signaling through the Ras/MAPK pathway [30]. Among Lewis 
antigens, Lewisy(Ley) is the product of two fucosylation reactions: the addition of Fuc α1,2 linked to 
Gal and of Fuc α1,3 linked to GlcNAc (Table 1). The first reaction is catalyzed by FUT1 or FUT2, the 
second by FUT4. Genetic manipulation studies of these fucosyltransferase genes demonstrate the 
importance of Ley for ERBB receptors activity and cell malignancy [50–55]. On the other hand, the 
presence of sialylated/fucosylated structures, presumably the sialyl Lex (sLex), on N-linked chains of 
EGFR reduces its ligand-induced dimerization and intracellular signaling, resulting in decreased 
invasion in lung cancer [46]. By contrast, expression of ERBB2 correlates with the expression of FUT3, 
the main fucosyltransferase responsible for the biosynthesis of the related antigen sialyl Lea (sLea) 
(Table 1) in gastric cancer specimens. Indeed, experiments of antigen blocking by anti sLea antibody 
in a gastric cancer cell line result in a dramatic downregulation of the ERBB2 protein [58]. 
Both α2,3 and/or α2,6 sialylation of EGFR reduce ligand binding and tyrosine phosphorylation 
[46] and increase Gefitinib sensitivity in Gefitinib-resistant cells[47]. The inverse correlation between 
EGFR signaling and sialylation (in this case, α2,6 sialylation mediated by ST6GAL1) was confirmed 
in a colon cancer cell model, although in this case reduced sialylation was associated with increased 
Gefitinib sensitivity [48]. Other members of the ERBB family appear to be negatively regulated by 
ST6GAL1 expression, albeit through an indirect and complex mechanism. In fact, reduction of 
ST6GAL1 expression, due to overexpression of mi-R199a, leads to a reduced protein level of the 
nectin-like Molecule 2/Cell Adhesion Molecule 1, which acts as an inhibitor of the ERBB2/ERBB3 
signaling [111]. A further confirmation of the inverse effect of sialylation on EGFR activity comes 
from a study showing the activation of EGFR signaling, as a consequence of plasma membrane 
sialidase NEU3 overexpression [112,113]. However, an inhibitory rather than an activatory effect on 
EGFR signaling has been reported for NEU1 overexpression in airway cells [114]. The O-
glycosylation of EGFR, mediated by GALNT2 or GALNT6, two of the 20 GalNAc transferases 
catalyzing the first step in O-linked biosynthesis (Table 1), results in enhanced malignancy of oral[64] 
and ovarian cancer [65], respectively. On the other hand, GALNT2 modification of EGFR reduces 
malignancy of hepatocarcinoma [66]. 
The β1,6-branched glycans and their biosynthetic enzyme MGAT5 play a very important role in 
enhancing EGFR activity. These mechanisms include the activation of p21-activated kinase 1, which 
leads to resistance to anoikis (a type of cell death triggered by the lack of adhesion to solid substrates) 
[34], the inhibition of the protein tyrosine phosphatase kappa (RPTPκ) (phosphatases usually 
counteract the activity of kinases, downregulating signaling) [35], and radioresistance [39], all related 
to the EGFR signaling pathway [38]. Knockdown of Mgat5 inhibits EGFR internalization and 
intracellular signaling [37] and reduces dephosphorylation of focal adhesion kinase [36]. 
4.1.2. Effect of Galectin Binding on ERBB Activity 
As previously mentioned, the presence of β1,6-branching promotes a galectin lattice formation 
(Figure 1), which regulates the permanence of receptors on the plasma membrane [100]. However, 
caveolin-1 can antagonize galectin lattice formation, in particular when the degree of β1,6-branching 
is relatively low. In fact, when lattice formation is poor, EGFR localizes in caveolin-1 microdomains 
(Figure 2) where downstream signaling is inhibited [115]. MUC1 is a heavily N- and O-glycosylated 
membrane glycoprotein composed of two subunits: the extracellular N-terminal and the membrane 
C-terminal domain joined by a non-covalent link [116]. In cancer cells, the transmembrane portion of 
MUC1 and EGFR physically interact [117], although in normal epithelial cells this interaction is 
prevented by their differential localization at the apical and basolateral cell side, respectively. The 
phosphorylation at the C-terminal of MUC1 cytoplasmic portion is mediated by EGFR and regulates 
its interaction with p53 and β-catenin, which is necessary for gene transcription [118]. Galectin-3 
plays a key role in the regulation of the intracellular trafficking and activation of MUC1 and EGFR 
[119–121]. The “Yamanaka factors” are a group of genes, including c-Myc, Sox2 and Oct4, whose 
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expression generates “induced pluripotent stem cells” (iPSC)[122]. Galectin-3 promotes a self-fueling 
loop generating cancer stem cells (CSCs) through stimulation of EGFR, which, in turn, leads to 
increased c-Myc protein stability and Sox2 transcription. Oct4, in turn, promotes galectin-3 
expression, enhancing a positive regulatory loop in lung CSCs [123]. In prostate cancer, 
overexpression of galectin-4 relates to malignancy because it binds on the O-linked carbohydrate 
antigen T (Table 1), activating EGFR/ERBB2 signaling [124]. On the other hand, a positive relationship 
among the expression of ST3GAL1, the enzyme thatconverts the T antigen in sialyl-T antigen (Table 
1), EGFR signaling and malignancy has also been documented [71]. 
4.1.3. Interaction of Gangliosides with ERBB Activity 
Ganglioside regulation of ERBB receptors activity is crucially dependent on the number of 
gangliosides actually residing in microdomains (Figure 2). Several studies have provided information 
on the role of GM3 in the localization of ERBB receptors in relation to their phosphorylation [125–
128]. Very recently, it has been reported that disialogangliosides, such as GD3 and GD2, enhance 
EGFR signaling, resulting in the expression of a cancer stem cell phenotype and a reduced sensitivity 
to Gefitinib [86]. In tetraspanin-enriched microdomains, various membrane receptors are organized 
by members of the tetraspanin superfamily. The importance of gangliosides in this structure is 
demonstrated by the fact that inhibition of their biosynthesis and expression of neuraminidase NEU3 
results in altered association of EGFR with microdomains [129]. A complex interplay among 
integrins, caveolin, tetraspanin CD82 and gangliosides is at the basis of the modulation of EGFR 
activity by urokinase-type plasminogen activator (uPA) [130–132]. The interaction of the GlcNAc 
termini of the N-linked chains of EGFR with the sialylatedlactosaminic chain of the ganglioside GM3 
(Figure 3A) provides an example of carbohydrate–carbohydrate interaction, which leads to 
downregulation of EGFR tyrosine kinase activity [76–80]. Interestingly, the cell surface β-
galactosyltransferase-1 (B4GALT1), which behaves like a lectin, has also been reported to bind to 
EGFR (putatively through its GlcNAc termini), reducing its activation [6,133]. GM3 is the precursor 
of higher gangliosides. In fibroblasts from patients affected by an inactivating mutation of the GM3 
synthase ST3GAL5 (Table 1), the ganglioside content (not only GM3) is 93% reduced. In these cells, 
the number of EGFR molecules is normal although the binding of EGF and the downstream signaling 
are reduced [134]. Probably, this effect is a balance between the loss of the inhibitory activity of GM3 
and the loss of the stimulatory activity played by more complex gangliosides, such as GD1a 
[75,90,91]. 
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Figure 3. Effect of gangliosides on RTK activity. (A) Two EGFR monomers (1), in the presence of EGF, 
dimerize resulting in phosphorylation of tyrosine residues at their cytoplasmic portion (2). The 
interaction of the GlcNAc termini of the EGFR N-linked chains with ganglioside GM3 inhibits 
signaling (3), while interaction with GD3 reinforces it (4). (B) The MET receptor is comprised of a 
heavily glycosylated extracellular α chain (in blue) and a transmembrane β chain (in red), which 
undergoes phosphorylation of tyrosine residues of its cytoplasmic domain upon HGF binding (1 and 
2). MET activation can be induced by interaction with disialogangliosides, such as GD3 and GD2, 
even in the absence of HGF (3). Sugar codes are as in the legend of Table 1. 
4.2. Receptor of the Hepatocyte Growth Factor 
The hepatocyte growth factor receptor (also known as c-Met), product of the MET gene, is 
expressed on epithelial cells of many organs and is composed by a highly glycosylated extracellular 
α-chain joined through a disulfide bond with the single-pass transmembrane β-chain containing the 
tyrosine kinase domain (Figure 3B) [135,136]. HGF (hepatocyte growth factor), the only known ligand 
of MET, is also identified as scatter factor for its ability to promote cell migration, besides cell growth. 
4.2.1. Direct Effect of Glycosylation on MET Activity 
MET contains 11 N-glycosylation sites. The inhibition of N-glycosylation results in the block of 
the intracellular transport of MET but, at the same time, in a partial activation of MET signaling in 
the absence of ligand [16]. Core fucosylationand Fut8 are important for MET regulation, as suggested 
by a mice model in which their suppression inhibits liver regeneration and liver carcinogenesis 
through inhibition of MET (and EGFR) signaling [25,26]. Bisecting GlcNAcon MET glycans enhances 
HGF-induced cell scattering in HepG2 cells [29]. This effect is remarkable, owing to the general 
growth suppressing activity of bisecting GlcNAc. Induction of sLexon MET by expression of 
sialyltransferase ST3GAL4 enhances MET signaling and invasion of gastric cancer cells [59], while 
ST6GAL1 deficiency causes a reduction of α2,6-sialylation of MET and consequently abolishes 
motility of HCT116 cells [44]. Modulation of O-glycosylation in gastric cancer cells by 
downregulation of GALNT2 (Table 1) causes increased expression and phosphorylation of MET, 
which results in increased invasion in vitro and in vivo [67]. Core 1 galactosyltransferase-1 
(C1GALT1), the enzyme elaborating the T antigen (Table 1), enhances tumor growth by increasing 
MET dimerization and activation [69]. 
4.2.2 Effect of Ganglioside Binding on MET Activity 
Regulation of MET activity by gangliosides is strongly dependent on their carbohydrate chains. 
In fact, ganglioside GM3 promotes HGF-stimulated motility of hepatocarcinoma cells via PI3K/Akt 
signaling, while it inhibits EGF-stimulated motility in the same cells [73]. In breast cancer cells, the 
disialoganglioside GD2 activates MET in the absence of HGF [87,88,137], leading to metastasis 
competence, stem cell like properties and activation of epithelial to mesenchymal transition 
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(EMT)[89]. EMT is a crucial process in embryonic development, tissue repair and metastasis through 
which epithelial cells acquire a mesenchymal-like phenotype, consisting of reduced cell adhesion and 
increased motility. In microdomains (Figure 2), the ganglioside GM2, but not GM3 or globoside, 
forms a complex with tetraspanin CD82, which inhibits HGF-induced activation of MET tyrosine 
kinase and its crosstalk with integrins [85]. Ganglioside GD1a negatively regulates HGF expression 
through caveolin-1 in murine osteosarcoma cells [92]. However, in canine kidney MDCK cells the 
highly similar ganglioside GD1α (the structures of the two gangliosides differ only for the position 
and the type of linkage of a sialic acid residue, Table 1), synthesized by sialyltransferase 
ST6GALNAC5, results in MET overexpression and phosphorylation and anchorage-independent 
growth [93]. 
4.3. Receptors of the Vascular Endothelial Growth Factors 
The vascular endothelial growth factors (VEGFs) and their RTKs (VEGFRs) constitute a major 
signaling system, which is necessary for the formation of the circulatory system (vasculogenesis), the 
growth of new blood vessels from those pre-existing (angiogenesis) and is crucial for cancer 
progression and metastasis formation. Among the three VEGFR members, only VEGFR2 is able to 
bind all types of VEGF [138]. VEGF-A is the target of the monoclonal antibody Bevacizumab, in 
clinical use for the treatment of several advanced cancers. 
4.3.1. Direct Effect of Glycosylation on VEGFR Activity 
The number of N-glycosylation sites of VEGFR1-3 is 13, 18 and 12, respectively. VEGFRs provide 
multiple examples of direct and indirect modulation by carbohydrates. The importance of N-
glycosylation on VEGF activity is supported by the observation that treatment of endothelial cells 
with a glucose analogue thatinterferes with N-glycosylation prevents the formation of new capillaries 
due to the inhibition of Akt and extracellular signal-regulated kinase (ERK) signaling downstream to 
VEGFR2 [17]. Mice KO for the core fucose synthesizing enzyme Fut8 display an emphysema-like 
phenotype. Among the possible explanations, one is based on the finding that Fut8 is required for 
VEGFR2 expression. In its absence, the pro-apoptotic factor ceramide is overexpressed, leading to 
increased apoptosis among the cells of the alveolar septa of the lungs [27]. 
4.3.2. Effect of Galectin Binding on VEGFR Activity 
Both tumor and stromal cells may be responsible for the presence of galectins in the tumor 
microenvironment [139]. Regardless the origin, galectins play a crucial role in neoangiogenesis and 
tumor promotion. Two glycan modifications decorating VEGFR2, namely α2,6-sialylation and β1,6-
branching, can alternatively regulate the activation of VEGF signaling in the absence of VEGF, a 
phenomenon at the basis of Bevacizumab resistance. Resistant tumors secrete higher amounts of 
galectin-1 and express on VEGFR2 β1,6-branched N-glycans, synthesized by MGAT5. Binding of 
galectin-1 to these glycans promotes clustering of the receptors, triggering VEGF-independent 
activation. On the contrary, the high α2,6-sialylation of Bevacizumab-sensitive cells inhibits galectin-
1 binding, maintaining the ligand requirement for receptor activation and Bevacizumab sensitivity 
[40,140]. Also galectin-3 contributes to activation of VEGFR2 by binding to its β1,6-branched glycans 
resulting in its plasma membrane retention [41]. Galectins-1 and -3 induce angiogenesis in different 
endothelial cell lines. While galectin-1 or -3 alone induce only the phosphorylation of VEGFR2, the 
presence of both galectins is required to induce the phosphorylation of both VEGFR1 and -2 
[41,141,142]. An inhibitory effect is played by galectin-9, which prevents the phosphorylation of 
VEGFR3 (and IGF1R), resulting in inhibition of gastric cancer cells proliferation[143]. Galectins can 
modulate VEGFR activity also indirectly by interacting with VEGFR-associated molecules. A first 
example is provided by neuropilin-1, which acts as a co-receptor of VEGFR for VEGF in endothelial 
cells [144]. Through binding to neuropilin-1, but not to VEGFRs, galectin-1 activates VEGFR2 
signaling, resulting in stimulation of the MAPK serine/threonine-protein kinase-1 (SAPK1)/c-Jun N-
terminal kinase (JNK) and enhanced proliferation and migration of vascular endothelial cells [145]. 
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In addition, galectin-1 bound to neuropilin-1 promotes vascular permeability in complex with 
VEGFR1 [146]. Pathological lymphangiogenesis (the sprouting of lymphatic vessels from pre-existing 
lymphatic vessels) is stimulated by galectin-8 through a crosstalk between podoplanin (a heavily 
glycosylated mucin-type glycoprotein) and integrin-associated VEGFR3[147]. While in several 
biological systems the effect of galectin-1 is to promote cancer growth, in the trophoblast tumor cells 
BeWo it inhibits proliferation. This is due to the fact that of the three RTKs out of 71 modulated by 
galectin-1 treatment, the signaling of RET and JAK2 was inhibited, while that of VEGFR3 was 
stimulated [148]. 
4.3.3. Effect of Ganglioside Binding on VEGFR Activity 
Interaction with glycolipids plays an important role in the regulation of VEGF system. 
Lactosylceramide, but not other related compounds, stimulates VEGF-induced angiogenesis [149], as 
observed after inhibition of the lactosylceramide synthase B4GALT5 [72]. On the contrary, 
ganglioside GM3 inhibits the VEGFR2 phosphorylation induced by VEGF and complex gangliosides 
as GD1a [82]. The mechanism involves both the ligand-receptor binding and the receptor 
dimerization [81]. Moreover, gangliosides, which are frequently shed by cancer cells in the 
microenvironment and in body fluids, mediate the activation of VEGFR, by decreasing its activation 
threshold [150]. 
4.4. Receptors for Fibroblast Growth Factors 
Fibroblast growth factor receptors (FGFRs) form a family of four RTKs (FGFR1-4) thatbind to 18 
fibroblast growth factors (FGFs), expressed in nearly all tissues, playing important roles during 
embryonic development and tissue repair. FGF2 is also known as basic fibroblast growth factor 
(bFGF). FGFs bind to heparan sulfate proteoglycans (HSPG), forming a ternary complex with FGFRs 
on the cell surface. The inactive FGFR monomer undergoes dimerization and trans-
autophosphorylation of several specific tyrosine residues upon binding of two FGF molecules linked 
to HSPGs. The main intracellular signaling pathways activated through stimulation of FGFR are RAS-
MAPK kinase, PI3K-Akt, phospholipase Cγ and STAT [151]. Achondroplasia, a common form of 
dwarfism, is due to gain of function mutations of FGFR3 gene, leading to receptor over-activation. 
4.4.1. Direct Effect of Glycosylation on FGFR Activity 
The number of N-glycosylation sites on FGFR1-4 is 8, 8, 6 and 5, respectively. Several studies 
highlight the role of N-glycosylation in the regulation of FGFR activity. The lack of N-glycans on 
FGFR may increase the assembly of the FGF-FGFR-HSPG complex, leading to over-activation [22]. 
An Asn328Ile point mutation in FGFR has been associated to hypochondroplasia due to the lack of 
glycosylation, rather than to the aminoacid substitution per se[152]. However, inhibition of the 
enzyme mannose phosphate isomerase, involved in the initial steps of N-glycan biosynthesis, 
indicates that N-glycosylation of FGFR is required for signaling [18]. 
Among the specific carbohydrate determinants regulating FGFR activity, in sperm the presence 
of the Leyantigen on polylactosaminic chains inhibits FGFR signaling [57]. The role of O-glycosylation 
on FGFR signaling is shown by the effects of inhibition of GALNT3, which increases FGF23 cleavage 
[153] and by galactosylation of O-glycans of FGFR2 due to overexpression of C1GALT1 (Table 1), 
which results in the activation of the receptor and exacerbation of the malignant phenotype of CRC 
cells [70]. 
4.4.2. Effect of Galectin and Ganglioside Binding on FGFR Activity 
The integrin-dependent activation of FGFR (and VEGFR) can be mediated also by the clustering 
operated by the binding of galectin-3 to the β1,6-branched N-linked chains of integrins [142]. FGFRs 
colocalize with gangliosides, tetraspanins, and integrins in ganglioside-enriched microdomains 
(Figure 2). In human embryonal fibroblasts, integrin activation, following adhesion to ECM 
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substrates, induces FGFR activation and cell proliferation even in the absence of FGF. This integrin–
FGFR interaction is strongly inhibited by GM3 and/or tetraspanins [83]. 
4.4.3. Effect of PolysialylatedN-CAM on FGFR Activity 
The adhesion properties of the neural cell adhesion molecule (N-CAM) are regulated by the 
length of the polysialic acid chains decorating its N-linked chains. Polysialylated N-CAM and HSPG 
share a polyanionic nature. This could explain the fact that FGFR signaling can be activated also by 
interaction with polysialylated N-CAM, which has been shown to interact directly with FGFR [63] 
and with FGF2 [154]. In particular, the migration of cells expressing polysialylated N-CAM on ECM 
was paralleled by activation of the FGFR and its downstream signaling components [155]. 
4.5. Transforming Growth Factor-β Receptors 
The transforming growth factor-β (TGFB) family of cytokines comprises four members (TGFB1-
4) with complex and double edge biological effects, mediating immune-suppression as well as tissue 
repair [156]. In cancer cells, TGFB mediates growth arrest but it can also promote tumor growth by 
inducing a tolerogenic microenvironment and EMT [157]. The TGFB receptors (TGFBRs) are homo- 
or heterodimeric Ser/Thr kinase receptors grouped in three types (TGFBR1-3), which signal mainly 
through the SMAD pathway. 
4.5.1. Direct Effect of Glycosylation on TGFRB Activity 
The number of N-glycosylation sites present on TGFBR1-3 is 1, 3 and 5. TGFBR1 completely 
lacking N-glycosylation, after treatment with glycosylation inhibitors or mutation of N-glycosylation 
sites, accumulates intracellularly, with consequent block of the TGFB signaling [19]. The core 
fucosylation is required for TGFB1 function [158] as shown by data from Fut8 KO mice, whose 
emphysema-like phenotype can be explained by impaired TGFB signaling [28]. Moreover, lack of 
core fucosylation attenuates the EMT of cultured human renal tubular cells [159–161] and the 
vascular calcification in a model of uremia [161]. The Lewis antigens sLex and sLea, products of 
fucosyltransferases FUT6 and FUT3 respectively (Table 1), expressed on TGFBR1, are necessary to 
induce EMT, in particular in colon cancer cells [60], while Ley expression on TGFBR enhances SMAD 
signaling [56,162]. Sialylation and microsatellite instability are associated in CRC. Because of 
inherited or sporadic inactivating mutations of DNA repair enzymes (mainly MSH2 and/or MLH1, 
involved in mismatch repair), about 15% of CRC shows the instability of short repeated sequences 
(microsatellites), acquiring the microsatellite-instable (MSI) phenotype. This phenotype is associated 
with high frequency of frameshift mutations in genes expressing microsatellite sequences in their 
coding regions. The TGFBR2 genes possess a stretch of 10 adenine residues, which frequently 
undergo frameshift mutations in MSI CRC, leading to TGFBR2 inactivation, a crucial mutational step 
for CRC progression. In the CRC cell line HCT116 expressing the biallelic inactivation of TGFBR2, 
the reconstitution with a wild type TGFBR2 gene leads to altered sialylation of a variety of 
glycoproteins [163,164], without any change in the expression of sialyltransferases [164], suggesting 
a relationship between sialylation and a classical mutational step in CRC. β1,6-branching is involved 
in the pathogenesis of liver disease through TGFB signaling. Steatohepatitis is a liver disease in which 
the accumulation of triglycerides in hepatocytes (steatosis) is accompanied by a chronic inflammatory 
condition that ultimately leads to liver fibrosis (cirrhosis). In the hepatic stellate cells (a type of 
collagen producing cells involved in liver fibrosis) of a murine model of steatohepatitis, Mgat5 
expression enhances TGFB signaling although it inhibits collagen production, fibrosis, lymphocyte 
infiltration and progression to steatohepatitis [42]. 
4.5.2. Glycosylation as Inducer and Product of EMT 
In some circumstances, self-fueling loops may be generated when a glycosyltransferase product 
promotes EMT, which, in turn, stimulates the expression of that glycosyltransferase (Figure 4). 
Examples of self-fueling loops are provided by the N-acetylglucosaminyl transferase 2 (GCNT2), 
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which synthesizes I-branched polylactosaminic chains (I blood group antigen) (Table 1) [62], by α2,6 
sialylation mediated by ST6GAL1 [45] and by GM3 synthase (ST3GAL5) and GM3 ganglioside [74]. 
A more complex relationship involves MGAT3 and its cognate bisecting GlcNAc, which are 
negatively associated to EMT by modification of E-cadherin [165]. In addition, bisecting GlcNAc 
synthesized by MGAT3 inhibits TGFB1-induced EMT [31] and is inhibited by TGFB1 [166]. Thus, 
TGFB1 can remove the brake to EMT represented by bisecting GlcNAc/MGAT3 (Figure 4).  
 
Figure 4. TGFB1 and EMT.Owing to the overexpression of their cognate glycosyltransferases, some 
carbohydrate structures, indicated on the right, stimulate EMT. In turn, EMT stimulates the 
glycosyltransferases responsible for the biosynthesis of EMT-promoting structures, originating a self-
fueling loop. MGAT3 and its cognate bisecting GlcNAc structure inhibit EMT, however, which 
inhibits MGAT3 expression, removing a brake to EMT. Numbers indicate the appropriate references. 
4.6. Insulin Receptor and Insulin-Like Growth Factor Receptors 
The insulin receptor (INSR) is a RTK thatcan bind insulin and insulin like growth factor-1 and -
2 (IGF-1 and IGF-2). It is composed of two identical chains, each formed by a α and a β chain linked 
through a cysteine bond; both are the product of alternative splicing and post-translational events 
from the same transcript of the INSR gene. Dysregulation of insulin system leads to diabetes. IGF-1 
and -2 are powerful inducers of tissue and body growth, downstream to the growth hormone 
pathway, and with an important role in cancer growth [167]. The insulin-like growth factor receptors 
-1 and -2 (IGF1R and IGF2R) are RTKs structurally similar to INSR. 
4.6.1. Direct Effect of Glycosylation on INS/IGFR Activity 
INSR contains 18 N-glycosylation sites, while IGF1R and IGF2R contain 16 and 18 N-
glycosylation sites, respectively. Tunicamycin inhibition of N-glycosylation results in reduced levels 
of IGF1R because of impaired intracellular transport and processing [15,168]. A close crosstalk exists 
between IGF1R and androgen receptor (AR), a transcription factor acting as a driver in prostate 
cancer. AR stimulation increases IGF1R expression in prostate cancer cells [169] and hexosamine 
production, resulting in increased N- and O-glycosylation [168]. In turn, N-glycosylation of IGF1R is 
necessary for its plasma membrane localization and full receptor activity [168]. In prostate cancer 
cells, androgen receptor and IGF1R form a feedback loop in which AR activates IGF1R [169], which, 
in turn, stimulates AR activity [168,170]. A strong relationship between INSR and IGF1R 
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glycosylation and sexual hormones is also suggested by the marked changes of IGF1R N-
glycosylation observed in pregnancy [171]. 
Among specific carbohydrate determinants, the relevance of Lewis antigens is indicated by the 
fact that FUT7-mediated expression of sLex on the α subunit of INSR in hepatocarcinoma cells is 
related to increased signaling [61], while in ovarian cancer the expression of Ley antigen is related to 
increased expression of IGF1R [172]. The importance of sialylation is revealed by the fact that 
desialylation of both INSR and IGF1R by NEU1 results in marked effects on cell proliferation in 
response to insulin treatment [173]. O-glycosylation mediated by GALNT2 overexpression (Table 1) 
attenuates the neoplastic phenotype in neuroblastoma by inhibiting IGF1R dimerization and 
signaling [68]. 
4.6.2. Interaction with E-Cadherin 
MGAT3 and bisecting GlcNAc play an important role in INSR/IGFR signaling through 
interaction with E-cadherin. In fact, exogenous E-cadherin administration inhibits insulin signaling, 
while stimulation with insulin or IGF-1 of cells overexpressing E-cadherin induces downregulation 
of glycans carrying bisecting glycans, altered intracellular localization of E-cadherin and the 
acquisition of a mesenchymal-like phenotype [32,33]. 
4.6.3. Effect of Ganglioside Binding on FGFR Activity 
One of the most clinically relevant consequences of diabetes is impaired wound healing. In 
mouse models of diabetes, the KO of GM3 synthase (ST3GAL1) prevents the diabetes-associated 
inhibition of wound healing [84]. In fact, proliferation and migration of keratinocytes and activation 
of IGF1R are suppressed by excess glucose in wild-type cells, but increased in GM3 KO mice, 
indicating that GM3 inhibits IGF1 signaling [84]. 
4.7. Glucagon Receptor 
Insulin and glucagon play opposite roles in glucose homeostasis. The glucagon receptor (GCGR) 
is a member of the class B G-protein coupled receptors, whose stimulation results in adenylate cyclase 
activation [174]. It contains 4 N-glycosylation sites. 
Regulation of GCGR Activity by Interaction of β1,6-Branching with Galectin-9 
In Mgat5 KO mice, the glucagon response is reduced, while insulin sensitivity is increased. The 
activity of Mgat5 and a high concentration of its donor substrate UDP-GlcNAc (which depends on 
the glucose level) increase the β1,6-branching of N-glycans of glucagon receptor. This leads to 
increased galectin-9 binding and glucagon receptor signaling [43], suggesting that, through the β1,6 
branching of glucagon receptor, the glucose level regulates its own homeostasis [43]. 
4.8. Tumor Necrosis Factor Receptors 
Both the tumor necrosis factor receptor-1 and -2 (TNFRSF1A and TNFRSF1B), members of the 
wide tumor necrosis factor receptor superfamily (TNFRSF), can bind tumor necrosis factor-α (TNFA). 
Upon binding to TNFA, receptors undergo trimerization and interact through their death domain 
with intracellular adaptor proteins, such as TRAF, activating several downstream signaling pathways 
related to inflammatory response (NF-kB), stress response (JNK) and apoptotic death (caspase-8) 
[175]. 
4.8.1. Direct Effect of Glycosylation on TNFRSF Activity 
TNFRSF1A and TNFRSF1B contain 3 and 2 N-glycosylation sites, respectively. Inhibition of N-
glycosylation of TNFRSF1A in microglial cells results in inhibition of ligand binding [20]. In 
macrophages, α2,6-sialylation of TNFRSF1A protects from apoptosis [49]. In Schwann cells 
stimulated by TNF, galactosyltransferase B4GALT1 triggers an autocrine loop in which the level of 
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B4GALT1 expression regulates MAPK activation, the release of inflammatory mediators and 
apoptosis [176,177]. 
Finally, a very peculiar type of glycosylation, the addition of GlcNAc to arginine of the death 
domains of TNFRSF1A, TRADD and adaptor proteins, is induced by a pathogenic bacterium. This 
modification disrupts the TNFA signaling, inhibiting apoptosis and necroptosis (a type of regulated 
necrotic cell death), and is a part of the bacterial defense against the host immune system [178]. 
5. Concluding Remarks 
In this review, we have shown that glycosylation can precisely modulate the activity of growth 
and death factor receptors by different mechanisms, involving the direct effect on receptor transport, 
ligand binding, dimerization, and signaling. Glycosylation can also affect receptor activity by binding 
to galectins or by interaction with glycolipids. It appears that most of the glycan structures can 
differentially promote or inhibit receptor activity depending on the type of receptor and the cellular 
context (Table 1). While some glyco-epitopes, including the β1,6-branching, the core fucose and 
diasialogangliosides, appear to exert an activating role in all the systems investigated, other 
carbohydrate structures (such as Sia6LacNAc and GM3) exert opposite effects on different receptors 
(Table 1). It can be hypothesized that the effect of the “pan-activatory”glyco-epitopes is related to a 
common intrinsic nature of the receptors, while the effect of other epitopes remains receptor-specific. 
The growth of cancer cells is sustained by an extremely complex network of signal transduction 
pathways often generated at the level of membrane receptors. In this light, the effect of the 
overexpression of a glycosyltransferase and of its cognate glyco-epitope on cancer growth can be 
strongly dependent on the receptor expression pattern, resulting in opposite effects in different 
cancers. The modulation by glycosylation of membrane receptor activity and cell signaling provides 
a paradigmatic example of how a post-translational modification can generate a flow of information 
from the cell membrane to the nucleus (outside-in), ultimately regulating gene expression. In some 
cases, this can originate self-fueling loops. Some membrane receptors or their ligands are the target 
of molecular drugs aimed at the inhibition of their activity; more effective next generation drugs will 
be likely produced in the near future. Owing to the crucial role played by glycosylation in the 
regulation of receptor activity, the development of drugs targeting glyco-epitopes should conceivably 
be considered as a therapeutically interesting strategy. 
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Abbreviations 
AKT protein kinase B 
AR androgen receptor 
bFGF basic growth factor receptor 
Cer ceramide 
CRC colorectal cancer 
CSC cancer stem cells 
CTLA-4 cytotoxic T-lymphocyte antigen 4 
ECM extracellular matrix 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
EMT epithelial to mesenchymal transition 
ER estrogen receptor 
ERK extracellular signal-regulated kinase 
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FAK focal adhesion kinase 
FGF fibroblast growth factor 




GALNT2 N-acetylgalactosaminyltransferase 2 
Glc glucose 
GlcNAc N-acetylglucosamine 
GCGR glucagon receptor 
HGF hepatocyte growth factor 
HSPG heparan sulfate proteoglycans 
IGF-1 insulin-like growth factor-1 
IGF1-R insulin-like growth factor-1 receptor 
INSR insulin receptor 
iPSC induced pluripotent stem cells 
JAK Janus kinase 
JNK c-Jun N-terminal 
Ley Lewisy 
Man man 
MAPK mitogen-activated protein kinase 
MSI microsatellite instability 
MUC1 mucin-1 
N-CAM neural cell adhesion molecule 
NEU1-4 neuraminidase 1-4 
PI3K phosphatidylinositol-4,5-biphosphate 3-kinase 
PIP3 phosphatidylinositol (3,4,5)-triphosphate 
PSA polysialic acid 
PST polysialyltransferase ST8SIA2 
RTK receptor tyrosine kinase 
SAPK1 serine/threonine-protein kinase-1 
Sia sialic acid 
sT sialyl-T 
Sia6LacNAc α2,6-sialylated lactosamine 
STAT signal transducer and activator of transcription 




TGFB transforming growth factor-β 
TNFA tumor necrosis factor-α 
TNFRSF1A and TNFRSF1B tumor necrosis factor receptor-1A and -1B 
TRADD TNFRSF1A-associated death domain 
TSPAN tetraspanin 
VEGF vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor 
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